Valor20202021202220232024TTMGastos comerciales, generales y administrativos——————Investigación y desarrollo——————Beneficio operativo——————Total de ingresos no operativos——————Gastos por intereses, netos de intereses capitalizados——————Ingresos no operativos, una vez deducidos los gastos por intereses——————Ingresos/gastos extraordinarios——————Beneficio antes de impuestos——————Participación en los beneficios——————Impuestos——————Participación minoritaria——————Otros ingresos/gastos después de impuestos——————Beneficio neto antes de actividades interrumpidas——————Operaciones suspendidas——————Beneficio neto——————Ajuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas——————Beneficio básico por acción——————Beneficio por acción diluido——————Número medio de acciones ordinarias——————Acciones diluidas——————EBITDA——————EBIT——————Costo de los ingresos——————Otros costes de producción——————Amortización y depreciación (flujo de caja)——————
Grifols, S.A. - American Depositary Shares
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care.